statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CureVac Announces Key Patent Litigation Dates

CureVac (CVAC) has released an update. CureVac N.V., a biopharmaceutical company specializing in mRNA technology, has announced the latest trial da...

CureVac: A Buy Rating Amidst Intellectual Property Litigation and Strong Valuation Metrics

Analyst Roy Buchanan from JMP Securities reiterated a Buy rating on CureVac (CVAC Research Report) and keeping the price target at $18.00. Roy Bu...

GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines

Idrees Abbas / SOPA Images / LightRocket via Getty Images

 Key TakeawaysGSK has purchased the rights to COVID-19 and flu vaccines being developed in collaboration with German biotechnology...

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion...

Vaccine Stocks Erupt After Bird Flu Cases Reported In US & Australia

Vaccine Stocks Erupt After Bird Flu Cases Reported In US & Australia

 Shares of vaccine companies surged on Wednesday following two reports of human bird flu infections, one in the US and...

Guggenheim Reiterates "Neutral" Rating for CureVac (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC - Get Free Report)s stock had its "neutral" rating reaffirmed by Guggenheim in a research report issued on Friday, Benzinga reports.
CureVac Trading Up 3.4 %
NASDAQ CVAC...

CureVac posts early efficacy results for GSK-partnered flu shot

CureVac posts early efficacy results for GSK-partnered flu shot...

CureVac announces Phase 2 interim data from influenza vaccine program

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Potentially differentiated, multivalent candidate encodes antigens matched to all four WHO-recommended flu strainsFor influenza A strains, geometric mean titers numerically exceeded those elicited by...

CureVac's Influenza Vaccine Shows Strong Phase 2 Results

Curevac N.V. (CVAC) has released an update. CureVac N.V., in partnership with GSK, reports encouraging interim results from their Phase 2 study on...

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Volume	333,730.00
52-Wk High	$10.14
52-Wk Low	$2.22

CVAC CureVac N.V.

About

Feed

News

Sentiment

Earnings

Fundamentals